All Releases
 |
Mylan Announces Completion of Add-On Offering of Senior Notes
Aug 13, 2010
|
7.5 KB |
|
| |
PITTSBURGH, Aug 13, 2010 /PRNewswire via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has completed a private placement of $300 million aggregate principal amount of Senior Notes due 2020. The notes were issued at an issue price of 105.5% with a coupon of 7.875%, or an effective yield to maturity of 7.087%. The notes wer...
|
|
Mylan Announces Pricing of Add-On Offering of Senior Notes
Jul 30, 2010
|
7.6 KB |
|
| |
PITTSBURGH, July 30, 2010 /PRNewswire via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today announced that it priced $300 million aggregate principal amount of Senior Notes due 2020 at an issue price of 105.5% with a coupon of 7.875%, or an effective yield to maturity of 7.087%. The notes are being offered as additional notes under an existing...
|
|
Mylan Announces Proposed Add-On Private Placement of its Senior Notes Due 2020
Jul 29, 2010
|
7.2 KB |
|
| |
PITTSBURGH, July 29, 2010 /PRNewswire via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today announced that it intends to privately place $300 million in aggregate principal amount of senior notes through a reopening of its Senior Notes due 2020, subject to market and other conditions. The notes are being offered as additional notes under an ex...
|
|
Mylan Reports Adjusted Diluted EPS of $0.37 for the Three Months Ended June 30, 2010
Jul 28, 2010
|
33.8 KB |
|
| |
PITTSBURGH, July 28, 2010 /PRNewswire via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today announced its financial results for the three and six months ended June 30, 2010.
Financial Highlights
Adjusted diluted earnings per share (EPS) of $0.37 for the three months ended June 30 compared to $0.32 for the same prior year period; Adjusted dil...
|
|
Mylan Reschedules Second Quarter Earnings Call for Wednesday July 28, at 5 p.m. ET
Jul 22, 2010
|
6.9 KB |
|
| |
PITTSBURGH, July 22, 2010 /PRNewswire via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) announced today that it is rescheduling its second quarter earnings conference call and live webcast due to a scheduling conflict. Mylan will now review the company's second quarter 2010 financial results, which ended June 30, 2010, on Wednesday, July 28, at ...
|
|
Mylan Launches the Generic Version of Solodyn(R), 45 mg, 90 mg and 135 mg Tablets, Announces Settlement Agreement with Medicis
Jul 22, 2010
|
7.3 KB |
|
| |
PITTSBURGH, July 22, 2010 /PRNewswire via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Matrix Laboratories Limited received final approval on July 20 from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Minocycline Hydrochloride Extended Release Tablets (Minocyc...
|
|
Mylan Announces Settlement Agreement for Namenda(R)
Jul 22, 2010
|
7.0 KB |
|
| |
PITTSBURGH, July 22, 2010 /PRNewswire via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has entered into settlement and license agreements with Forest Laboratories and Merz Pharmaceuticals related to Namenda(R) Tablets, 5 mg and 10 mg, known generically as Memantine Hydrochloride (HCl) Tablets.
Pursuant to the settlement...
|
|
Mylan Declares Quarterly Preferred Stock Dividend
Jul 19, 2010
|
6.0 KB |
|
| |
PITTSBURGH, July 19, 2010 /PRNewswire via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today announced that in accordance with its 2.139 million preferred stock issuance, the company has declared its quarterly dividend of $16.25 per share (based on the annual dividend rate of 6.5% and a liquidation preference of $1,000.00 per share) payable on ...
|
|
Mylan Receives Approval for Generic Version of Catapres-TTS(R)
Jul 19, 2010
|
6.4 KB |
|
| |
PITTSBURGH, July 19, 2010 /PRNewswire via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/da...
|
|
Mylan to Acquire Bioniche Pharma Global Injectable Pharmaceuticals Business
Jul 14, 2010
|
10.5 KB |
|
| |
PITTSBURGH, July 14, 2010 /PRNewswire via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today announced plans to acquire Bioniche Pharma Holdings Limited, a privately held, global injectable pharmaceutical company for $550 million in cash. Bioniche Pharma will provide Mylan not only an immediate entry into the North American injectables market b...
|
|
Mylan Receives Approval for Nabumetone Tablets
Jul 14, 2010
|
6.4 KB |
|
| |
PITTSBURGH, July 14, 2010 /PRNewswire via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Nabumetone Tablets USP, 500 mg and 750 mg. The product was determi...
|
|
Mylan Schedules Second Quarter 2010 Financial Results Conference Call and Live Webcast
Jul 12, 2010
|
6.8 KB |
|
| |
PITTSBURGH, July 12, 2010 /PRNewswire via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) announced today that it will host a conference call and live webcast on Thursday, July 29, 2010, at 10 a.m. ET, to review the company's financial results for the second quarter 2010, which ended June 30, 2010. Mylan will release its financial results on July ...
|
|
Mylan Receives Approval for Generic Version of Arimidex(R) Tablets
Jun 29, 2010
|
6.0 KB |
|
| |
PITTSBURGH, June 29, 2010 /PRNewswire via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Anastrozole Tablets, 1 mg, the generic version of AstraZeneca's Ari...
|
|
Mylan Receives Approval for Generic Version of Procardia XL(R) Tablets
Jun 24, 2010
|
6.0 KB |
|
| |
PITTSBURGH, June 24, 2010 /PRNewswire via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Nifedipine Extended-release Tablets USP, 30 mg, 60 mg and 90 mg, th...
|
|
Mylan Receives Approval for Generic Version of Zocor(R) Tablets
Jun 18, 2010
|
6.0 KB |
|
| |
PITTSBURGH, June 18, 2010 /PRNewswire via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Simvastatin Tablets USP, 5 mg, 10 mg, 20 mg, 40 mg and 80 mg, the ...
|
|
Mylan Receives Approval for Hydroxyzine Hydrochloride Tablets
Jun 17, 2010
|
6.3 KB |
|
| |
PITTSBURGH, June 17, 2010 /PRNewswire via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Hydroxyzine Hydrochloride Tablets 10 mg, 25 mg and 50 mg. The product w...
|
|
Mylan Receives Approval for Generic Version of Neurontin(R) Tablets
Jun 4, 2010
|
6.0 KB |
|
| |
PITTSBURGH, June 4, 2010 /PRNewswire via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Gabapentin Tablets USP, 600 mg and 800 mg, the generic version of P...
|
|
Mylan Introduces Online Resource Centre for Continuing Education of Canadian Pharmacists
Jun 2, 2010
|
7.9 KB |
|
| |
...
|
|
Mylan Receives Approval for Generic Version of Valtrex(R)
May 26, 2010
|
6.4 KB |
|
| |
PITTSBURGH, May 26, 2010 /PRNewswire via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Valacyclovir Hydrochloride Tablets, 500 mg (base) and 1000 mg (base...
|
|
Mylan Launches Temazepam Capsules USP, 7.5 mg
May 25, 2010
|
6.3 KB |
|
| |
PITTSBURGH, May 25, 2010 /PRNewswire via COMTEX News Network/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Temazepam Capsules USP, 7.5 mg.
This additional strength, which had U.S. sales of approximately $56 million for the 12 months ending March 31, 2010, according to IMS Health, complemen...
|
|
|